

Neuro-HiTech, Inc.

a Delaware Corporation

OTC Disclosures for the Quarter ended September 30, 2018

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Neuro-HiTech, Inc.

Prior names:

Northern Way Resources, Inc. (NV):	February 1, 2005 – January 12, 2006
Northern Way Resources, Inc. (DE):	January 12, 2006 – January 25, 2006
Neuro-HiTech Pharmaceuticals, Inc.:	January 25, 2006 – May 15, 2007
Neuro-HiTech, Inc.:	May 15, 2007 – September 16, 2016
New Health Pharmaceuticals, Inc.:	September 16, 2016 – May 26, 2017
Neuro-HiTech, Inc.:	May 26, 2017 – present

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 16255 Aviation Loop Drive

Address 2: Brooksville, FL 34604

Phone: (888) 627-9139

Email: dambrose@tgunited.com

Website(s): n/a

IR Contact

n/a

3) Security Information

Trading Symbol: NHPI

Exact title and class of securities outstanding: common stock

CUSIP: 641244108

Par or Stated Value: \$0.000001

Total shares authorized: 1,994,999,900 as of: 10/18/18

Total shares outstanding: 1,248,789,109 as of: 10/18/18

Additional class of securities (if necessary):

Trading Symbol: n/a

Exact title and class of securities outstanding: Class A Common Stock

CUSIP: n/a

Par or Stated Value: \$0.001

Total shares authorized: 100 as of: 10/18/18

Total shares outstanding: 0 as of: 10/18/18

Additional class of securities (if necessary):

Trading Symbol: n/a

Exact title and class of securities outstanding: Preferred Stock

CUSIP: n/a

Par or Stated Value: \$0.001

Total shares authorized: 5,000,000 as of: 10/18/18

Total shares outstanding: 0 as of: 10/18/18

Transfer Agent

Name: Pacific Stock Transfer Company

Address 1: 6725 Via Austi Pkwy, Suite 300

Address 2: Las Vegas, Nevada 89119

Phone: (702) 361-3033

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

n/a

B. Any jurisdictions where the offering was registered or qualified;

n/a

C. The number of shares offered;

n/a

D. The number of shares sold;

n/a

E. The price at which the shares were offered, and the amount actually paid to the issuer;

n/a

F. The trading status of the shares; and

n/a

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

n/a

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

The following unaudited financial statements are incorporated by reference:

Financial Statement Period	Dated Posted to OTCIQ.com
3 and 9 months ended September 30, 2018 and 2017	October 22, 2018

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations;

The Company has historically been engaged in the business of development, marketing, sales and distribution of specialty pharmaceuticals. Currently, the Company's business operations are dormant.

- B. Date and State (or Jurisdiction) of Incorporation:

January 12, 2006 (Delaware). Originally incorporated in Nevada on February 1, 2005

C. the issuer's primary and secondary SIC Codes;

2834

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

historically, specialty pharmaceuticals; operations current dormant

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company does not lease or own any property. The Company's CEO, David Ambrose, provides office space on a month-to-month basis.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

David Ambrose
CEO, CFO and Director

Gary Dutton
COO

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

No

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Title of class	Name and address of beneficial owner	Amount of Beneficial Ownership	Percent of Class
Common	David Ambrose CEO, CFO and Director Brooksville, FL	351,333,333	28.13%
Common	Gary Dutton COO Southside, AL	0	0%
Common	Total all executive officers and directors	351,333,333	28.13%
Common	Other 5% Shareholders		
	None.		

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Joe Laxague, Esq.

Firm: Laxague Law, Inc.

Address 1: 1 East Liberty, Suite 600

Address 2: Reno, NV 89501

Phone: (775) 234-5221

Email: joe@laxaguelaw.com

Accountant or Auditor

Firm: Carrollton Partners LLC

Address 1: 77-79 E. Main St. Suite 406

Address 2: Westminster, MD 21157

Phone: (410) 861-0150

Email: rleimbach@carrolltonpartners.com

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v1.1 April 25, 2013)

Investor Relations Consultant

n/a

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

n/a

10) Issuer Certification


The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, David Ambrose, certify that:

1. I have reviewed this Quarterly Disclosure Statement of Neuro-HiTech, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 23, 2018



David Ambrose, CEO, CFO, and Director